MacroGenics
MGNX
131 hedge funds and large institutions have $594M invested in MacroGenics in 2016 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 16 closing their positions.
2,187% more call options, than puts
Call options by funds: $526K | Put options by funds: $23K
83.41% more ownership
Funds ownership: 0% → 83.41% (+83%)
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 132 → 131 (-1)
29% less capital invested
Capital invested by funds: $835M → $594M (-$241M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$11.7M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$7.33M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.28M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.17M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$21.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.1M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$6.04M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.97M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.83M |
MGNX Hedge Fund Activity: Q4 2016 in Review
131 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q4 2016, worth a combined $594M — down 29% from $835M a quarter earlier.
Fund positioning in MGNX was balanced in Q4 2016: 16 funds opened new positions, 16 closed out, 47 added to existing stakes and 42 trimmed.
The largest buyer was BB Biotech, adding an estimated $11.7M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $21.2M sold.
- 131 institutional investors held MacroGenics (MGNX) as of Q4 2016, down from 132 in Q3 2016.
- Funds reported $594M of MacroGenics stock for Q4 2016, down 29% quarter-over-quarter.
- 16 funds opened new MacroGenics positions in Q4 2016 and 16 closed out, a net change of 0 holders.
- The largest MacroGenics buyer in Q4 2016 was BB Biotech, an estimated $11.7M added.
- The largest MacroGenics seller in Q4 2016 was Cormorant Asset Management, an estimated $21.2M sold.
Based on aggregated 13F filings for Q4 2016.